US FDA Weighs Whether Interstitial Cystitis Should Be Studied Separately From Bladder Pain
Executive Summary
Advisory committee to vote on whether patients with interstitial cystitis, marked by Hunner's lesions, should be studied separately from the broader, more heterogeneous category of patients with bladder pain syndrome; recommendations could impact Aquinox and Urigen, which have drugs for IC/BPS in clinical development.
You may also be interested in...
Aquinox, Astellas Mull Options As Rosiptor Fails
Astellas’ late-stage bet on Aquinox’s urology drug now looks highly unlikely to pay off following the molecule’s “definitive” failure in a Phase III trial, which is also forcing the originator to consider its business and R&D options.
Bladder Pain, Interstitial Cystitis And The Move Toward Patient-Focused Drug Development
Patients with the conditions experience the same symptoms, US FDA advisory committee concludes. Industry sponsors had advocated for combined trials, but panel did not agree with firms' recommendations on study duration and outcome measures.
FDA's Advisory Cmte. Meeting On Bladder Pain Syndrome May Signal Policy Changes
The Bone, Reproductive and Urologic Drugs Advisory Committee will consider endpoints, clinical trial designs and other issues related to development in the disease.